Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.
Mei M, Chen L, Godfrey J, Song J, Egelston C, Puverel S, Budde LE, Armenian S, Nikolaenko L, Nwangwu M, Guo W, Gao L, Lee P, Chen R, Daniels S, Kennedy N, Peters L, Zain J, Rosen S, Forman S, Popplewell L, Kwak L, Herrera AF.
Mei M, et al. Among authors: rosen s.
Blood. 2023 Oct 19;142(16):1359-1370. doi: 10.1182/blood.2023020485.
Blood. 2023.
PMID: 37339586